Menveo (Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M)

The active ingredient consists of capsular polysaccharides from four meningococcal serogroups chemically linked to the CRM197 protein carrier. This conjugation enables the immune system to recognize the polysaccharides as T‑cell dependent antigens, stimulating robust B‑cell responses and the production of high‑affinity antibodies that neutralize the bacteria.

The dosing schedule for Menveo is determined by the prescribing healthcare professional based on age, risk factors, and local immunization guidelines. The prescriber will select the appropriate number of doses and timing to achieve optimal protection.

Safety data for Menveo in pregnancy are limited, and the vaccine should only be used when the potential benefits outweigh any theoretical risks. Breastfeeding is not a contraindication, but women should discuss vaccination with their healthcare provider to make an informed decision.

To place an order, submit an enquiry on the Menveo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Menveo is a quadrivalent conjugate vaccine covering serogroups A, C, W‑135 and Y, offering T‑cell dependent immunity and longer lasting protection compared with polysaccharide‑only formulations. Some alternatives may cover fewer serogroups or use different carrier proteins, but Menveo’s broad coverage and conjugate technology are considered advantageous for many immunization programs.

Menveo must be stored refrigerated at 2‑8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Menveo is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique. The exact administration schedule is defined by the prescriber according to approved immunization guidelines.

Serious adverse events are rare but may include anaphylaxis, severe allergic reactions, and seizures. Immediate medical attention is required if symptoms such as difficulty breathing, swelling of the face or throat, hives, or convulsions occur after vaccination.

Menveo should not be administered to individuals with a known severe allergy to any component of the vaccine, including the CRM197 protein carrier. Persons who have experienced a severe allergic reaction to a previous dose of Menveo should also avoid further vaccination.